Table of Contents 2
List of Tables 5
List of Figures 5
Nektar Therapeutics Spshot 6
Nektar Therapeutics Overview 6
Key Information 6
Key Facts 6
Nektar Therapeutics - Research and Development Overview 7
Key Therapeutic Areas 7
Nektar Therapeutics - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combition Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combition Treatment Modalities 15
Nektar Therapeutics - Pipeline Products Glance 16
Nektar Therapeutics - Late Stage Pipeline Products 16
Phase III Products/Combition Treatment Modalities 16
Nektar Therapeutics - Clinical Stage Pipeline Products 17
Phase II Products/Combition Treatment Modalities 17
Phase I Products/Combition Treatment Modalities 18
Nektar Therapeutics - Early Stage Pipeline Products 19
Preclinical Products/Combition Treatment Modalities 19
Discovery Products/Combition Treatment Modalities 20
Nektar Therapeutics - Drug Profiles 21
etirinotecan pegol 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
NKTR-181 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NKTR-214 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NKTR-171 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NKTR-173 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NKTR-195 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NKTR-218 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NKTR-223 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NKTR-230 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
NKTR-255 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Proteins for Hematological Disorders 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drug to Inhibit Kise for Cancer 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Protein to Agonize Cytokine Receptor for Inflammation 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Protein to Agonize Cytokine Receptor for Viral Infections 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Nektar Therapeutics - Pipeline Alysis 38
Nektar Therapeutics - Pipeline Products by Target 38
Nektar Therapeutics - Pipeline Products by Route of Administration 39
Nektar Therapeutics - Pipeline Products by Molecule Type 40
Nektar Therapeutics - Pipeline Products by Mechanism of Action 41
Nektar Therapeutics - Recent Pipeline Updates 42
Nektar Therapeutics - Dormant Projects 50
Nektar Therapeutics - Discontinued Pipeline Products 51
Discontinued Pipeline Product Profiles 51
NKTR-105 51
NKTR-192 51
Nektar Therapeutics - Company Statement 52
Nektar Therapeutics - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57